Pharma

When European hospitals began rationing antibiotics and diabetics faced insulin shortages, the continent confronted an uncomfortable truth: its medicine supply chains had become dangerously fragile. Now, as the European Union prepares to implement its Critical Medicines Act—a sweeping legislative response to recurring drug shortages—an unexpected beneficiary emerges thousands of kilometres away. India’s pharmaceutical industry, already […]

Indian pharmaceutical manufacturing has long been synonymous with generic medicines and cost-effective healthcare solutions, but December 1, 2025, marked an inflection point that could redefine the industry’s global identity. When Wockhardt’s shares catapulted 19 per cent following a landmark US Food and Drug Administration approval, it wasn’t merely another market rally—it was a historic validation.

The global pharmaceutical landscape is witnessing a seismic shift, and Indian drugmakers are positioned at its epicentre. As the US biosimilars market prepares to quadruple from $22.6 billion in 2025 to a staggering $90 billion by 2034, a revolutionary FDA draft guideline has thrown open the gates for Indian manufacturers. By potentially halving development costs

Western sanctions were meant to isolate Russia—instead, they’ve opened the door for India. While European and American pharmaceutical companies retreat from the Russian market under pressure from their governments, Indian manufacturers are advancing, negotiating joint ventures, planning production facilities, and positioning themselves as the primary suppliers to a nation desperate for pharmaceutical self-sufficiency. Russia already